Organika Health Products Inc. SAMe 400 mg Tablets
Organika Health Products Inc. SAMe 400 mg Tablets, NPN 80071979: natural health product licensed in Canada. Medicinal ingredients: S-(5'-Desoxyadenosin-5'-yl)-l-methionine.
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| S-(5'-Desoxyadenosin-5'-yl)-l-methionine Source : S-Adenosyl-L-methionine disulfate tosylate | 400 milligramme | Not calculated |
Non-medicinal ingredients
Cellulose microcristalline, Silice, Amidon prégélatinisé, Acide stéarique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Comprimé | 3 Tous les jours |
Uses authorised in Canada
Helps relieve the symptoms and pain of osteoarthritis. Helps support healthy liver function. Helps support a healthy mood balance.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contra-Indications
Do not use if you are pregnant or breastfeeding; or if you have been diagnosed with bipolar disorder.
- Known Adverse Reactions
Flatulence, nausea, vomiting, diarrhea, constipation, dry mouth or headaches may occur. Some people may experience anxiety, restlessness, insomnia, and/or temporary increase in heart rate (tachycardia), in which case discontinue.
- Cautions and Warnings
Consult a health care practitioner if you are taking anti-depressants, hepatotoxic drugs or any other prescription medication. Consult a health care practitioner prior to use if you have cardiovascular disease. Consult a health care practitioner if symptoms persist or worsen.
Product record
- Licence holder
- Organika Health Products Inc.
- NPN or DIN-HM
- 80071979
- Status
- Active licence
- Licence date
- 12 August 2016
- Revision date
- 4 January 2017
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
Source
Official Health Canada record, licence 80071979
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Organika Health Products Inc. SAMe 400 mg Tablets: composition and ingredients”, https://compoatlas.com/en/supplements/canada/80071979-organika-health-products-inc-same-400-mg-tablets, updated 4 January 2017.